Ohno Yuta, Niwa Takashi, Hirai Keita, Suzuki Keiko, Yamada Yuto, Hayashi Yuichi, Hayashi Hideki, Suzuki Akio, Itoh Yoshinori
Department of Pharmacy, Gifu University Hospital, Gifu.
Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka.
Ther Drug Monit. 2018 Aug;40(4):507-511. doi: 10.1097/FTD.0000000000000521.
Because clinical data to confirm the safety and effectiveness of fosphenytoin, a prodrug of phenytoin, are insufficient, the length of administration of fosphenytoin is restricted. Nevertheless, some cases require fosphenytoin administration for more than a few days. The aim of this study was to retrospectively investigate the serum concentration of phenytoin in adult Japanese patients who received intravenous fosphenytoin therapy for more than 3 days.
Patients injected with intravenous fosphenytoin for more than 3 days at Gifu University Hospital between January 2012 and September 2014 were enrolled. Individual pharmacokinetic parameters were predicted by Bayesian estimation using NONMEM software, and the maintenance dose of fosphenytoin required to maintain the therapeutic trough concentration (10-20 mcg/mL) was calculated from the parameters.
Among a total of 8 patients, the serum trough concentration of phenytoin decreased with each day after repeated injection of fosphenytoin. The incidence rate of significant convulsive seizures was increased time dependently (0% on day 1, 12.5% on day 2, 25% on day 3, and 66.7% on day 4 and after). Phenytoin clearance showed a time-dependent increase. The maintenance dose of fosphenytoin required to maintain the therapeutic trough concentration was simulated to be 779.8 ± 316.8 mg/d, a dose that was markedly higher than the actual maintenance dose (414.1 ± 55.7 mg/d).
Prolonged use of fosphenytoin, for such patients as those with autoimmune-mediated encephalopathy accompanied with reflux disease and/or ileus, time dependently decreased the serum concentration of phenytoin and increased the risk of convulsion. Therefore, the maintenance dose should be increased to maintain the therapeutic serum concentration.
由于用于证实苯妥英前体药物磷苯妥英安全性和有效性的临床数据不足,磷苯妥英的给药时长受到限制。然而,有些病例需要使用磷苯妥英超过数天。本研究的目的是回顾性调查接受静脉注射磷苯妥英治疗超过3天的成年日本患者的苯妥英血清浓度。
纳入2012年1月至2014年9月期间在岐阜大学医院接受静脉注射磷苯妥英超过3天的患者。使用NONMEM软件通过贝叶斯估计预测个体药代动力学参数,并根据这些参数计算维持治疗谷浓度(10 - 20 mcg/mL)所需的磷苯妥英维持剂量。
在总共8例患者中,重复注射磷苯妥英后,苯妥英的血清谷浓度随时间下降。严重惊厥发作的发生率随时间增加(第1天为0%,第2天为12.5%,第3天为25%,第4天及以后为66.7%)。苯妥英清除率呈时间依赖性增加。维持治疗谷浓度所需的磷苯妥英维持剂量经模拟为779.8 ± 316.8 mg/d,该剂量明显高于实际维持剂量(414.1 ± 55.7 mg/d)。
对于伴有反流性疾病和/或肠梗阻的自身免疫性介导性脑病等患者,长期使用磷苯妥英会使苯妥英血清浓度随时间下降,并增加惊厥风险。因此,应增加维持剂量以维持治疗性血清浓度。